Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical subsidiary has received approval from Health Canada for its application for the generic version of Celebrex for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Subscribe to our email newsletter
Teva’s Celecoxib is also indicated for the short-term management of moderate to severe acute pain in adults, in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic and pain following dental extraction.
In Canada, Celebrex had annual sales of about $151m, based on IMS Brogan sales data as of September 2014.
The company said that Celecoxib is available immediately in pharmacies across the country.
Teva Canada senior vice-president and general manager Doug Sommerville said: "Arthritis is one of the most prevalent chronic conditions and the economic impact on the Canadian economy in healthcare costs and lost productivity is estimated by The Arthritis Society to be $33bn each year.
"Teva Canada is very pleased to be able to offer our more affordable, bioequivalent version of Celebrex to patients today.
"New generic launches in Canada over the last three years have saved patients and payers more than $2.3bn versus the cost of the equivalent brand name drug product – and with today’s launch, we are demonstrating our ongoing commitment to playing a critical role in ensuring the sustainability of the healthcare system."
Osteoarthritis, rheumatoid arthritis and ankylosing spondylitis are three of the most common forms of arthritis, which is a form of joint disorder that involves inflammation of one or more joints.